Dr. Gregory Brunin, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 1,774
Licensed in Colorado since 2016, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Baylor College of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license R2066 (first issued 2017; active) · CO license DR.0056570 (first issued 2016; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Rashid and Rice Eye Associates, P.l.l.c. (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,774
- Services billed
- 5,077
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 1,305 | 1,227 |
| Established patient problem focused exam of visual system | 707 | 415 |
| Imaging of retina | 515 | 453 |
| Measurement of corneal curvature and depth of eye | 311 | 190 |
| Removal of cataract with insertion of prosthetic lens | 241 | 148 |
| Imaging of optic nerve | 229 | 227 |
| Ct scan of cornea | 228 | 213 |
| Established patient office or other outpatient visit, 30-39 minutes | 220 | 215 |
| Exam of visual field with extended testing | 200 | 192 |
| Photography of the retina | 174 | 173 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in San Antonio, TX | 777 |
| Latanoprost Other prescribers in San Antonio, TX | 663 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in San Antonio, TX | 529 |
| Ketorolac Tromethamine Other prescribers in San Antonio, TX | 430 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in San Antonio, TX | 162 |
| Fluorometholone Other prescribers in San Antonio, TX | 133 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in San Antonio, TX | 128 |
| Brimonidine Tartrate Other prescribers in San Antonio, TX | 88 |
| Timolol Maleate Other prescribers in San Antonio, TX | 79 |
| Restasis (cyclosporine) Other prescribers in San Antonio, TX | 66 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 19 payments worth $649 in total to this clinician.
| Rxsight Inc | $386 |
|---|---|
| Mallinckrodt Hospital Products Inc. | $72.10 |
| AbbVie Inc. | $64.58 |
| Bausch & Lomb Americas Inc. | $39.49 |
| Alcon Vision LLC | $34.51 |
| Dompe US, Inc. | $29.14 |
| Apellis Pharmaceuticals, Inc. | $23.52 |
| Food and Beverage | $649 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $352,815 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
Oyster Point Pharma, Inc. · Terminated · NCT06400511 - PMCS-010
Rxsight Inc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.